Αποτελέσματα αναζήτησης - "деэскалация"

Πηγή: Russian Sklifosovsky Journal "Emergency Medical Care"; Том 10, № 4 (2021); 769-777 ; Журнал им. Н.В. Склифосовского «Неотложная медицинская помощь»; Том 10, № 4 (2021); 769-777 ; 2541-8017 ; 2223-9022

Θεματικοί όροι: деэскалация, STE-ACS, NSTE-ACS, thrombosis, antiplatelet therapy, dual antiplatelet therapy (DAPT), escalation, de-escalation, ОКСспST, ОКСбпST, тромбообразование, антиагрегантная терапия, двойная антитромбоцитарная терапия (ДАТТ), эскалация

Περιγραφή αρχείου: application/pdf

Relation: https://www.jnmp.ru/jour/article/view/1282/1004; https://www.jnmp.ru/jour/article/view/1282/1106; Camm AJ, Lüscher TF, Maurer G, Serruys PW. (eds.) ESC CardioMed. 3rd ed. Oxford University Press; 2018. https://doi.org/10.1093/med/978019 8784906.001.0001; Здравоохранение в России 2015: статистический сборник. Москва: Росстат; 2015.; Braunwald E, Morrow DA. Unstable Angina: Is It Time for a Requiem? Circulation. 2013;127(24):2452–2457. PMID: 23775194 https://doi.org/10.1161/CIRCULATIONAHA113.001258; Sheridan PJ, Crossman DC. Critical review of unstable angina and nonST elevation myocardial infarction. Postgrad Med J. 2002;78(926):717– 726. PMID: 12509688 https://doi.org/10.1136/pmj.78.926.717; Basit H, Malik A, Huecker MR. Non ST Segment Elevation (NSTEMI) Myocardial Infarction. [Last Update: September 6, 2021]. StatPearls [Internet]. Available at: https://www.ncbi.nlm.nih.gov/books/ NBK513228/ [Accessed November 22, 2021].; Goyal A, Zeltser R. Unstable Angina. [Last Update: July 26, 2021]. StatPearls [Internet]. Available at: https://www.ncbi.nlm.nih.gov/books/NBK442000/ [Accessed November 22, 2021].; Akbar H, Foth C, Kahloon RA, Mountfort S. Acute ST Elevation Myocardial Infarction. [Last Update: August 9, 2021]. StatPearls [Internet]. Available at: https://www.ncbi.nlm.nih.gov/books/NBK532281/ [Accessed November 22, 2021].; Thygesen K, Alpert JS, Jaffe AS, Chaitman BR, Bax JJ, Morrow DA, et al. Fourth universal definition of myocardial infarction (2018). Eur Heart J. 2019;40(3):237–269. https://doi.org/10.1093/eurheartj/ehy462; Falk E, Shah PK, Fuster V. Coronary Plaque Disruption. Circulation. 1995;92(3):657–671. PMID: 7634481 https://doi.org/10.1161/01. CIR.92.3.657; Карагодин В.П., Бобрышев Ю.В., Орехов А.Н. Воспаление, иммунокомпетентные клетки, цитокины — роль в атерогенезе. Патогенез. 2014;12(1):21–35.; Аронов Д.М., Лупанов В.П. Некоторые аспекты патогенеза атеросклероза. Атеросклероз и дислипидемии. 2011;1(2):48–56.; Crea F, Libby P. Acute Coronary Syndromes: The Way Forward From Mechanisms to Precision Treatmen. Circulation. 2017;136(12):1155– 1166. PMID: 28923905 https://doi.org/10.1161/CIRCULATIONAHA.117.029870; O’Gara PT, Kushner FG, Ascheim DD, Casey Jr DE, Chung MK, de Lemos JA, et al. 2013 ACCF/AHA guideline for the management of STelevation myocardial infarction: a report of the ACCF/AMA Task Force on Practice Guidelines. Circulation. 2013;127(4):e362–e425. PMID: 23247304 https://doi.org/10.1161/CIR.0b013e3182742cf6; Mekaj Y, Daci F, Mekaj A. New insights into the mechanisms of action of aspirin and its use in the prevention and treatment of arterial and venous thromboembolism. Ther Clin Risk Manag. 2015;11:1449–1456. PMID: 26445544 https://doi.org/10.2147/TCRM.S92222; Layne K, Ferro A. Antiplatelet Therapy in Acute Coronary Syndrome. Eur Cardiol. 2017;12(1):33–37. PMID: 30416549 https://doi.org/10.15420/ecr.2016:34:2; Cattaneo M. ADP receptor antagonists. In: Michelson AD. (ed.) Platelets. 2nd ed. San Diego: Elsevier/Academic Press; 2007. Prt.5, Ch.61. p.1127– 1144. https://doi.org/10.1016/B978-012369367-9/50823-5; Mehta SR, Yusuf S, Peters RJ, Bertrand ME, Lewis BS, Natarajan MK, et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet. 2001;358(9281):527–533. PMID: 11520521 https://doi.org/10.1016/s0140-6736(01)05701-4; Chen ZM, Jiang LX, Chen YP, Xie JX, Pan HC, Peto R, et al. Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet. 2005;366(9497):1607– 1621. PMID: 16271642 https://doi.org/10.1016/S0140-6736(05)67660-X; Shuvanan R. Clopidogrel resistance: the way forward. Indian Heart J. 2014;66(5):530–534. PMID: 25443607 https://doi.org/10.1016/j.ihj.2014.08.012; Storey RF, Angiolillo DJ, Patil SB, Desai B, Ecob R, Husted S, et al. Inhibitory effects of ticagrelor compared with clopidogrel on platelet function in patients with acute coronary syndromes: the PLATO (PLATelet inhibition and patient Outcomes) PLATELET substudy. J Am Coll Cardiol. 2010;56(18):1456–1462. PMID: 20832963 https://doi.org/10.1016/j.jacc.2010.03.100; Granger CB, Berger PB. Understanding the Adverse Effects of Ticagrelor in Practice. JAMA Cardiol. 2016;1(4):381–383. PMID: 27438332 https://doi.org/10.1001/jamacardio.2016.1018; Dellborg M, Bonaca MP, Storey RF, Steg PG, Kyung AI, Cohen M, et al. Efficacy and safety with ticagrelor in patients with prior myocardial infarction in the approved European label: insights from PEGASUSTIMI 54. Eur Heart J Cardiovasc Pharmacother. 2019;5(4):200–206. PMID: 31218354 https://doi.org/10.1093/ehjcvp/pvz020; Jakubowski JA, Winters KJ, Naganuma H, Wallentin L. Prasugrel: a novel thienopyridine antiplatelet agent. A review of preclinical and clinical studies and the mechanistic basis for its distinct antiplatelet profile. Cardiovasc Drug Rev. 2007;25(4):357–374. PMID: 18078435 https://doi.org/10.1111/j.1527-3466.2007.00027.x; Wiviott SD, Braunwald E, McCabe CH, Montalescot G, Ruzyllo W, Gottlieb S, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007;357(20):2001–2015. PMID:17982182 https://doi.org/10.1056/NEJMoa0706482; De Luca L, Capranzano P, Patti G, Parodi G. Switching of platelet P2Y12 receptor inhibitors in patients with acute coronary syndromes undergoing percutaneous coronary intervention: Review of the literature and practical considerations. Am Heart J. 2016;176:44–52. PMID: 27264219 https://doi.org/10.1016/j.ahj.2016.03.006; Deerhake ME, Tricoci P. Vorapaxar: The Drug and its Applications. May 18, 2016. American college of cardiology. Available at: https://www.acc.org/latest-in-cardiology/articles/2016/05/18/13/58/vorapaxar [Accessed November 23, 2021].; Offermanns S. Activation of platelet function through G proteincoupled receptors. Circ Res. 2006;99(12):1293–1304. PMID: 17158345 https://doi.org/10.1161/01.RES.0000251742.71301.16; Roffi M, Chew DP, Mukherjee D, Bhatt DL, White JA, Moliterno DJ, et al. Platelet glycoprotein IIb/IIIa inhibition in acute coronary syndromes. Gradient of benefit related to the revascularization strategy. Eur Heart J. 2002;23(18):1441–1448. PMID: 12208224 https://doi.org/10.1053/euhj.2002.3160; Quinn MJ, Plow EF, Topol EJ. Platelet Glycoprotein IIb/IIIa Inhibitors, Recognition of a Two-Edged Sword? Circulation. 2002;106(3):379–385. PMID: 12119257 https://doi.org/10.1161/01.CIR.0000019581.22812.B2; Eisen A, Bhatt DL Optimal duration of dual antiplatelet therapy after acute coronary syndromes and coronary stenting. Heart. 2017;103(11):871–884. PMID: 27888209 https://doi.org/10.1136/ heartjnl-2015-309022; Ibanez B, James S, Agewall S, Antunes MJ, Bucciarelli-Ducci C, Bueno H, et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2018;39(2):119–177. PMID: 28886621 https://doi.org/10.1093/eurheartj/ehx393; Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK, et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med. 2001;345(7):494–502. PMID: 11519503 https://doi.org/10.1056/NEJMoa010746; Costa F, van Klaveren D, James S, Heg D, Räber L, Feres F, et al. Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score: a pooled analysis of individual-patient datasets from clinical trials. Lancet. 2017;389(10073):1025–1034. PMID: 28290994 https://doi.org/10.1016/S0140-6736(17)30397-5; Yeh RW, Secemsky EA, Kereiakes DJ, Normand S-LT, Gershlick AH, Cohen DJ, et al. Development and Validation of a Prediction Rule for Benefit and Harm of Dual Antiplatelet Therapy Beyond 1 Year After Percutaneous Coronary Intervention. JAMA. 2016;315(16):1735–1749. PMID: 27022822 https://doi.org/10.1001/jama.2016.3775; Sabouret P, Rushton-Smith SK, Kerneis M, Silvan J, Collet J-P, Montalescot G. Dual antiplatelet therapy: optimal timing, management, and duration. Eur Heart J Cardiovasc Pharmacother. 2015;1(3):198–204. PMID: 27533996 https://doi.org/10.1093/ehjcvp/pvv015; Wilson SJ, Newby DE, Dawson D, Irving J, Berry C. Duration of dual antiplatelet therapy in acute coronary syndrome. Heart. 2017;103(8):573–580. PMID: 28249994 https://doi.org/10.1136/heartjnl-2016-309871; Valgimigli M, Costa F, Lokhnygina Y, Clare RM, Wallentin L, Moliterno DJ, et al. Trade-off of myocardial infarction vs. bleeding types on mortality after acute coronary syndrome: lessons from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) randomized trial. Eur Heart J. 2017;38(11):804– 810. PMID: 28363222 https://doi.org/10.1093/eurheartj/ehw525; Шамраев Р.Л., Илюхин О.В., Иваненко В.В., Мерзляков С.Г., Лопатин Ю.М. Последствия эскалации и де-эскалации двойной антитромбоцитарной терапии у больных с острым коронарным синдромом в условиях реальной клинической практики. Российский кардиологический журнал. 2019;24(3):90–97. http://dx.doi.org/10.15829/1560-4071-2019-3-90-97; Kupka D, Sibbing D. De-Escalation of P2Y12 Receptor Inhibitor Therapy after Acute Coronary Syndromes in Patients Undergoing Percutaneous Coronary Intervention. Korean Сirc J. 2018;48(10):863–872. https://doi.org/10.4070/kcj.2018.0255; Angiolillo DJ, Rollini F, Storey RF, Bhatt DL, James S, Schneider DJ, et al. International Expert Consensus on Switching Platelet P2Y12 ReceptorInhibiting Therapies. Circulation. 2017;136(20):1955–1975. PMID: 29084738 https://doi.org/10.1161/CIRCULATIONAHA.117.031164; Deharo P, Quilici J, Camoin-Jau L, Johnson TW, Bassez C, Bonnet G. Benefit of Switching Dual Antiplatelet Therapy After Acute Coronary Syndrome According to On-Treatment Platelet Reactivity: The TOPICVASP Pre-Specified Analysis of the TOPIC Randomized Study. JACC Cardiovasc Interv. 2017;10(24):2560–2570. PMID: 29268886 https://doi.org/10.1016/j.jcin.2017.08.044; Angiolillo DJ, Saucedo JF, Deraad R, Frelinger AL, Gurbel PA, Costigan TM, et al. Increased platelet inhibition after switching from maintenance clopidogrel to prasugrel in patients with acute coronary syndromes: results of the SWAP (SWitching Anti Platelet) study. J Am Coll Cardiol. 2010;56(13):1017–1023. PMID: 20846599 https://doi.org/10.1016/j.jacc.2010.02.072; Gurbel PA, Bliden KP, Butler K, Antonino MJ, Wei C, Teng R, et al. Response to ticagrelor in clopidogrel nonresponders and responders and effect of switching therapies: the RESPOND study. Circulation. 2010;121(10):1188–1199. PMID: 20194878 https://doi.org/10.1161/CIRCULATIONAHA.109.919456; Bagai A, Wang Y, Wang TY, Curtis JP, Gurm HS, Shah B, et al. Inhospital switching between clopidogrel and prasugrel among patients with acute myocardial infarction treated with percutaneous coronary intervention: insights into contemporary practice from the national cardiovascular data registry. Circ Cardiovasc Interv. 2014;7(4):585–593. PMID: 25097196 https://doi.org/10.1161/CIRCINTERVENTIONS.114.00 1555; Kim H-S, Kang J, Hwang D, Han J-K, Yang H-M, Kang H-J, et al. Prasugrelbased de-escalation of dual antiplatelet therapy after percutaneous coronary intervention in patients with acute coronary syndrome (HOSTREDUCE-POLYTECH-ACS): an open-label, multicentre, non-inferiority randomised trial. Lancet. 2020;396(10257):1079–1089. PMID: 32882163 https://doi.org/10.1016/S0140-6736(20)31791-8; Zettler ME, Peterson ED, McCoy LA, Effron MB, Anstrom KJ, Henry TD, et al. Switching of adenosine diphosphate receptor inhibitor after hospital discharge among myocardial infarction patients: Insights from the Treatment with Adenosine Diphosphate Receptor Inhibitors: Longitudinal Assessment of Treatment Patterns and Events after Acute Coronary Syndrome (TRANSLATE-ACS) observational study. Am Heart J. 2017;183:62–68. PMID: 27979043 https://doi.org/10.1016/j.ahj.2016.10.006; https://www.jnmp.ru/jour/article/view/1282

Διαθεσιμότητα: https://www.jnmp.ru/jour/article/view/1282
https://doi.org/10.23934/2223-9022-2021-10-4-769-777

View record from BASE

4

Academic Journal

Treatment strategy for HPV-positive oropharyngeal cancer: a literature review ; Стратегия лечения ВПЧ-положительного рака ротоглотки: обзор литературы

Συγγραφείς: O. A. Saprina, О. А. Саприна

Πηγή: Head and Neck Tumors (HNT); Том 12, № 2 (2022); 108-115 ; Опухоли головы и шеи; Том 12, № 2 (2022); 108-115 ; 2411-4634 ; 2222-1468 ; 10.17650/2222-1468-2022-12-2

Θεματικοί όροι: химиолучевое лечение, p16-positive oropharyngeal cancer, squamous cell carcinoma, treatment deescalation, chemoradiotherapy, ассоциированный с вирусом папилломы человека, р16-положительный орофарингеальный рак, плоскоклеточный рак, деэскалация лечения

Περιγραφή αρχείου: application/pdf

Relation: https://ogsh.abvpress.ru/jour/article/view/772/526; Давыдов М.И. Энциклопедия клинической онкологии. М.: РЛС-2004, 2004.; NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®). Cancer of the Oropharynx. Version 2.2018. Available at: https://www.nccn.org/guidelines/category_1.; Ragin C.C.R., Taioli E. Survival of squamous cell carcinoma of the head and neck in relation to human papillomavirus infection: review and meta-analysis. Int J Cancer 2007;121(8):1813-20. DOI:10.1002/ijc.22851; Allen C.T., Lewis J.S., El-Mofty S.K. et al. Human papillomavirus and oropharynx cancer: biology, detection and clinical implications. Laryngoscope 2010;120(9):1756-72. DOI:10.1002/lary.20936.; O'Sullivan B., Huang S.H., Su J. et al. Development and validation of a staging system for HPV-related oropharyngeal cancer by the International Collaboration on Oropharyngeal cancer Network for Staging (ICON-S): a multicentre cohort study. Lancet Oncol 2016;17(4):440-510. DOI:10.1016/S1470-2045(15)00560-4.; Chaturvedi A.K., Engels E.A., Anderson W.F., Gillison M.L. Incidence trends for human papillomavirus-related and -unrelated oral squamous cell carcinomas in the United States. J Clin Oncol 2008;26:612-9.; Chaturvedi A.K., Engels E.A., Pfeiffer R.M. et al. Human papillomavirus and rising oropharyngeal cancer incidence in the United States. J Clin Oncol 2011;29(32):4294-301. DOI:10.1200/JCO.2011.36.4596.; Corey A.S., Hudgins P.A. Radiographic imaging of human papillomavirus related carcinomas of the oropharynx. Head Neck Pathol 2012;6(Suppl. 1):S25-40. DOI:10.1007/s12105-012-0374-3.; D'Souza G., Agrawal Y., Halpern J. et al. Oral sexual behaviors associated with prevalent oral human papillomavirus infection. J Infect Dis 2009;199(9): 1263-9. DOI:10.1086/597755.; D'Souza G., Zhang H.H., D'Souza W.D. et al. Moderate predictive value of demographic and behavioral characteristics for a diagnosis of HPV16-positive and HPV16-negative head and neck cancer. Oral Oncol 2010;46(2):100-4. DOI:10.1016/j.oraloncology.2009.11.004.; Vokes E.E., Agrawal N., Seiwrt T.Y. HPV-associated head and neck cancer. J Natl Cancer Inst 2015;107(12):djv344. DOI:10.1093/jnci/djv344.; Ang K.K., Harris J., Wheeler R. Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med 2010;363(1):24-35. DOI:10.1056/NEJMoa0912217.; Harrison L.B., Sessions R.B., Kies M.S. Head and neck cancer. A multidisciplinary approach. 2014. 4th edn. Lippincott Williams and Wilkins, Philadelphia, USA.; Nguyen-Tan P.F., Zhang Q., Ang K.K. et al. Randomized phase III trial to test accelerated versus standard fractionation in combination with concurrent cisplatin for head and neck carcinomas in the Radiation Therapy Oncology Group 0129 trial: long-term report of efficacy and toxicity. J Clin Oncol 2014;32(34):3858-66. DOI:10.1200/JCO.2014.55.3925.; Chera B.S., Amdur R.J., Tepper J.E. et al. Mature results of a prospective study of deintensified chemoradiotherapy for low-risk human papillomavirus-associated oropharyngeal squamous cell carcinoma. Cancer 2018;124(11):2347-54. DOI:10.1002/cncr.31338.; Chera B.S., Amdur R.J., Green R. et al. Phase II trial of de-intensified chemoradiotherapy for human papillomavirus-associated oropharyngeal squamous cell carcinoma. J Clin Oncol 2019;37(29): 2661-9. DOI:10.1200/JCO.19.01007.; Marur S., Li S., Cmelak A.J. et al. E1308: phase II trial of induction chemotherapy followed by reduced-dose radiation and weekly cetuximab in patients with HPV-associated resectable squamous cell carcinoma of the oropharynx -ECOG-ACRIn Cancer Research Group. J Clin Oncol 2016;35(5):490-7. DOI:10.1200/JCO.2016.68.3300.; Cmelak A., Li S., Marur S. et al. Symptom reduction from IMRT dose deintensification: Results from ECOG 1308 using the Vanderbilt Head and Neck Symptom Survey version 2 (VHNSS V2). J Clin Oncol 2015;33(15 suppl):6021a.; Misiukiewicz K., Gupta V., Miles B.A. et al. Standard of care vs reduced-dose chemoradiation after induction chemotherapy in HPV+ oropharyngeal carcinoma patients: The Quarterback trial. Oral Oncol 2019;95:170-7. DOI:10.1016/j.oraloncology.2019.06.021.; Seiwert T.Y., Foster C.C., Blair E.A. et al. OPTIMA: a phase II dose and volume deescalation trial for human papillomaviruspositive oropharyngeal cancer. Ann Oncol 2019;30(2):297-302. DOI:10.1093/annonc/mdy522.; Nevens D., Duprez F., Daisne J.F. et al. Reduction of the dose of radiotherapy to the elective neck in head and neck squamous cell carcinoma; a randomized clinical trial. Effect on late toxicity and tumor control. Radiother Oncol 2017;122(2):171-7. DOI:10.1016/j.radonc.2016.08.009.; Nevens D., Duprez F., Daisne J.-F. et al. Recurrence patterns after a decreased dose of 40Gy to the elective treated neck in head and neck cancer. Radiother Oncol 2017;123(3):419-23. DOI:10.1016/j.radonc.2017.03.003.; Al-Mamgani A., van Werkhoven E., Navran A. et al. Contralateral regional recurrence after elective unilateral neck irradiation in oropharyngeal carcinoma: a literature-based critical review. Cancer Treat Rev 2017;59:102-8. DOI:10.1016/j.ctrv.2017.07.004.; Jellema A.P., Slotman B.J., Doornaert P. et al. Unilateral versus bilateral irradiation in squamous cell head and neck cancer in relation to patient-rated xerostomia and sticky saliva. Radiother Oncol 2007;85(1):83-9. DOI:10.1016/j.radonc.2007.03.002.; Loganadane G., Kelly J.R., Lee N.C. et al. Incidence of radiographically occult nodal metastases in HPV+ oropharyngeal carcinoma: Implications for reducing elective nodal coverage. Pract Radiat Oncol 2018;8(6):397-403. DOI:10.1016/j.prro.2018.03.009.; Leeman J.E., Gutiontov S., Romesser P. et al. Sparing of high retropharyngeal nodal basins in patients with unilateral oropharyngeal carcinoma treated with intensity modulated radiation therapy. Pract Radiat Oncol 2017;7(4):254-9. DOI:10.1016/j.prro.2016.11.002.; Tam M., Riaz N., Kannarunimit D. et al. Sparing bilateral neck level IB in oropharyngeal carcinoma and xerostomia outcomes. Am J Clin Oncol 2015;38(4):343-7. DOI:10.1097/COC.0000000000000064.; Mohindra P., Urban E., Pagan J.D. et al. Selective omission of level V nodal coverage for patients with oropharyngeal cancer: clinical validation of intensity-modulated radiotherapy experience and dosimetric significance. Head Neck 2016;38(4):499-505. DOI:10.1002/hed.23924.; Rosenberg A.J., Agrawal N., Pearson A. et al. Low risk HPV-associated oropharyngeal squamous cell carcinoma treated with induction chemoimmunotherapy followed by TORS or radiotherapy. Multidisciplinary Head Neck Cancers Symposium; February 27-29, 2020; Scottsdale, AZ.; Garden A.S., Morrison W.S., Stugis E.M. et al. IMRT for oropharyngeal carcinoma: patiet outcome and patterns of failure. Int J Radiat Oncol Biol Phys 2011;81(2): 15-6. DOI:10.1016/j.ijrobp.2011.06.031.; Pernot M., Luporsi E., Hoffstetter S. et al. Complications following definitive irradiation for cancers of the oral cavity and the oropharynx (in a series of 1134 patients). Int J Radiat Oncol Biol Phys 1997;37(3):577-85. DOI:10.1016/s0360-3016(96)00612-8.; Henstrom D.K., Moore E.J., Olsen K.D. et al. Transoral resection for squamous cell carcinoma of the base of the tongue. Arch Otolaryngol Head Neck Surg 2009;135(12):1231-8. DOI:10.1001/archoto.2009.177.; De Almeida J.R., Byrd J.K., Wu R. et al. A systematic review of transoral robotic surgery and radiotherapy for early oropharynx cancer. Laryngoscope 2014;124(9):2096-102. DOI:10.1002/lary.24712.; Moore E.J., Olsen S.M., Laborde R.R. et al. Long-term functional and oncologic results of transoral robotic surgery for oropharyngeal squamous cell carcinoma. Mayo Clin Proc Mayo Clin 2012;87(3):219-25. DOI:10.1016/j.mayocp.2011.10.007.; Smith R.V., Schiff B.A., Garg M. et al. The impact of transoral robotic surgery on the overall treatment of oropharyngeal cancer patients. Laryngoscope 2015;125(10):S10-5. DOI:10.1002/lary.25534.; Grant D.C., Hinni M.L., Salassa J.R. et al. Oropharyngeal cancer: a case of single modality with transoral laser microsurgery. Arch Otolaryngol Head Neck Surg 2009;135(12):1225-30. DOI:10.1001/archoto.2009.185.; Haughey B.H., Hinni M.I., Salassa J.R. et al. Transoral laser microsurgery as primary treatment for advanced stage oropharyngeal cancer: a Unated States multicenter study. Head Neck 2011;33(12):1683-94. DOI:10.1002/hed.21669.; Steiner W., Fierek O., Ambrosch P. et al. Transoral laser microsurgery for squamous cell carcinoma of the base of the tongue. Arch Otolaryngol Head Neck Surg 2003;129(1):36-43. DOI:10.1001/archotol.129.1.36.; Mirghani H., Blanchard P. Treatment de-escalation for HPV-driven oropharyngeal cancer: where do we stand? Clin Transl Radiat Oncol 2018;8:4-11. DOI:10.1016/j.ctro.2017.10.005.; Ferris R.L., Flamand Y., Weinstein G.S. et al. Transoral robotic surgical resection followed by randomization to low- or standard-dose IMRT in resectable p16+ locally advanced oropharynx cancer: a trial of the ECOG-ACRIn Cancer Research Group (E3311). J Clin Oncol 2020;38(15 suppl):6500a.; Ma D.J., Price K.A., Moore E.J. et al. Phase II evaluation of aggressive dose de-escalation for adjuvant chemoradiotherapy in human papillomavirus-associated oropharynx squamous cell carcinoma. J Clin Oncol 2019;37(22):1909-18. DOI:10.1200/JCO.19.00463.; Sinha P., Lewis J.S., Piccirillo J.F. et al. Extracapsular spread and adjuvant therapy in human papillomavirus-related, p16-positive oropharyngeal carcinoma. Cancer 2012;118(14):3519-30. DOI:10.1002/cncr.26671; https://ogsh.abvpress.ru/jour/article/view/772

Διαθεσιμότητα: https://ogsh.abvpress.ru/jour/article/view/772
https://doi.org/10.17650/2222-1468-2022-12-2-108-115

View record from BASE

5

Academic Journal

Current views on antiplatelet therapy in acute coronary syndrome patients: the place of clopidogrel ; Современный взгляд на антитромбоцитарную терапию у пациентов с острым коронарным синдромом: место клопидогрела

Συγγραφείς: O. O. Shakhmatova, О. О. Шахматова

Πηγή: Aterotromboz = Atherothrombosis; Том 12, № 1 (2022); 30-45 ; Атеротромбоз; Том 12, № 1 (2022); 30-45 ; 2658-5952 ; 2307-1109 ; 10.21518/2307-1109-2022-1

Θεματικοί όροι: фармакогенетика, myocardial infarction, acute coronary syndrome, de-escalation, bleeding, pharmacogenetics, инфаркт миокарда, острый коронарный синдром, деэскалация, кровотечения

Περιγραφή αρχείου: application/pdf

Relation: https://www.aterotromboz.ru/jour/article/view/269/286; Monroe D.M., Hoffman M., Roberts H.R. Platelets and thrombin generation. Arterioscler Thromb Vasc Biol. 2002;22(9):1381–1389. https://doi.org/10.1161/01.atv.0000031340.68494.34.; Yusuf S., Zhao F., Mehta S.R., Chrolavicius S., Tognoni G., Fox K.K. et al. Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med. 2001;345(7):494–502. https://doi.org/10.1056/NEJMoa010746.; Sabatine M.S., Cannon C.P., Gibson C.M., López-Sendón J.L., Montalescot G., Theroux P. et al. Addition of Clopidogrel to Aspirin and Fibrinolytic Therapy for Myocardial Infarction with ST-Segment Elevation. N Engl J Med. 2005;352(12):1179–1189. https://doi.org/10.1056/NEJMoa050522.; Chen Z.M., Jiang L.X., Chen Y.P., Xie J.X., Pan H.C., Peto R. et al. COMMIT (ClOpidogrel and Metoprolol in Myocardial Infarction Trial) collaborative group. Addition of clopidogrel to aspirin in 45 852 patients with acute myocardial infarction: randomised placebo-controlled Trial. Lancet. 2005;366(9497):1607–1621. https://doi.org/10.1016/S0140-6736(05)67660-X.; Mehta S.R., Yusuf S., Peters R.J., Bertrand M.E., Lewis B.S., Natarajan M.K. et al. Clopidogrel in Unstable angina to prevent Recurrent Events trial (CURE) Investigators. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet. 2001;358(9281):527–533. https://doi.org/10.1016/s0140-6736(01)05701-4.; Wallentin L., Becker R.C., Budaj A., Cannon C.P., Emanuelsson H., Held C. et al. PLATO Investigators, Freij A, Thorsén M. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009;361(11):1045–1057. https://doi.org/10.1056/NEJMoa0904327.; Wiviott S.D., Braunwald E., McCabe C.H., Montalescot G., Ruzyllo W., Gottlieb S. et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007;357(20):2001–2015. https://doi.org/10.1056/NEJMoa0706482.; You S.C., Rho Y., Bikdeli B., Kim J., Siapos A., Weaver J. et al. Association of Ticagrelor vs Clopidogrel With Net Adverse Clinical Events in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention. JAMA. 2020;324(16):1640–1650. https://doi.org/10.1001/jama.2020.16167.; Sun M., Cui W., Li L. Comparison of Clinical Outcomes Between Ticagrelor and Clopidogrel in Acute Coronary Syndrome: A Comprehensive Meta-Analysis. Front Cardiovasc Med. 2022;8:818215. https://doi.org/10.3389/fcvm.2021.818215.; Gimbel M., Qaderdan K., Willemsen L., Hermanides R., Bergmeijer T., de Vrey E. et al. Clopidogrel versus ticagrelor or prasugrel in patients aged 70 years or older with non-ST-elevation acute coronary syndrome (POPular AGE): the randomised, open-label, non-inferiority trial. Lancet. 2020;395(10233):1374–1381. https://doi.org/10.1016/S0140-6736(20)30325-1.; Parodi G., Storey R.F. Dyspnoea management in acute coronary syndrome patients treated with ticagrelor. Eur Heart J Acute Cardiovasc Care. 2015;4(6):555–560. https://doi.org/10.1177/2048872614554108.; Gurbel P.A., Bliden K.P., Butler K., Tantry U.S., Gesheff T., Wei C. et al. Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/ OFFSET study. Circulation. 2009;120(25):2577–2585. https://doi.org/10.1161/CIRCULATIONAHA.109.912550.; Motovska Z., Hlinomaz O., Kala P., Hromadka M., Knot J., Varvarovsky I. et al. 1-year outcomes of patients undergoing primary angioplasty for myocardial infarction treated with prasugrel versus ticagrelor. J Am Coll Cardiol. 2018;71(4):371–381. https://doi.org/10.1016/j.jacc.2017.11.008.; Zeymer U., Cully M., Hochadel M. Adherence to dual antiplatelet therapy with ticagrelor in patients with acute coronary syndromes treated with percutaneous coronary intervention in real life. Results of the REAL-TICA registry. Eur Heart J Cardiovasc Pharmacother. 2018;4(4):205–210. https://doi.org/10.1093/ehjcvp/pvy018.; Collet J.P., Thiele H., Barbato E., Barthélémy O., Bauersachs J., Bhatt D.L. et al. 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J. 2020:ehaa575. https://doi.org/10.1093/eurheartj/ehaa575.; Ibanez B., James S., Agewall S., Antunes M.J., Bucciarelli-Ducci C., Bueno H. et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2018;39(2):119–177. https://doi.org/10.1093/eurheartj/ehx393.; Барбараш О.Л., Дупляков Д.В., Затейщиков Д.А., Панченко Е.П., Шахнович Р.М., Явелов И.С. и др. Острый коронарный синдром без подъема сегмента ST электрокардиограммы. Клинические рекомендации 2020. Российский кардиологический журнал. 2021;(4):4449. https://doi.org/10.15829/1560-4071-2021-4449.; Аверков О.В., Дупляков Д.В., Гиляров М.Ю., Новикова Н.А., Шахнович Р.М., Яковлев А.Н. и др. Острый инфаркт миокарда с подъемом сегмента ST электрокардиограммы. Клинические рекомендации 2020. Российский кардиологический журнал. 2020;(11):4103. https://doi.org/10.15829/29/1560-4071-2020-4103.; Сагайдак О.В., Ощепкова Е.В., Попова Ю.В., Посненкова О.М., Киселев А.Р., Гриднев В.И., Чазова И.Е. Анализ оказания медицинской помощи больным с острым коронарным синдромом в 2019 году (по данным федерального регистра острого коронарного синдрома). Кардиологический вестник. 2020;(3):37–45. Режим доступа: https://cardioweb.ru/files/Cardiovest/Kardiovestnik_3_2020.pdf.; Эрлих А.Д., Грацианский Н.А. Российский регистр острого коронарного синдрома РЕКОРД-3. Характеристика пациентов и лечение до выписки из стационара. Кардиология. 2016;(4):16–24. https://doi.org/10.18565/cardio.2016.4.16-24.; Berwanger O., Lopes R.D., Moia D.D., Fonseca F.A., Jiang L., Goodman S.G. et al. Ticagrelor Versus Clopidogrel in Patients With STEMI Treated With Fibrinolysis: TREAT Trial. J Am Coll Cardiol. 2019;73(22):2819–2828. https://doi.org/10.1016/j.jacc.2019.03.011.; Lawton J.S., Tamis-Holland J.E., Bangalore S., Bates E.R., Beckie T.M., Bischoff J.M. et al. 2021 ACC/AHA/SCAI Guideline for Coronary Artery Revascularization: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2022;145(3):e18–e114. https://doi.org/10.1161/CIR.0000000000001038.; Fernández-Avilés F., Alonso J.J., Peña G., Blanco J., Alonso-Briales J., López-Mesa J. еt al. Primary angioplasty vs. early routine post-fibrinolysis angioplasty for acute myocardial infarction with ST-segment elevation: the GRACIA-2 non-inferiority, randomized, controlled trial. Eur Heart J. 2007;28(8):949–960. https://doi.org/10.1093/eurheartj/ehl461.; Cantor W.J., Fitchett D., Borgundvaag B., Ducas J., Heffernan M., Cohen E.A. et al. Routine early angioplasty after fibrinolysis for acute myocardial infarction. N Engl J Med. 2009;360(26):2705–2718. https://doi.org/10.1056/NEJMoa0808276.; Généreux P., Giustino G., Witzenbichler B., Weisz G., Stuckey T.D., Rinaldi M.J. et al. Incidence, Predictors, and Impact of Post-Discharge Bleeding After Percutaneous Coronary Intervention. J Am Coll Cardiol. 2015;66(9):1036–1045. https://doi.org/10.1016/j.jacc.2015.06.1323.; Ducrocq G., Schulte P.J., Becker R.C., Cannon C.P., Harrington R.A., Held C. et al. Association of spontaneous and procedure-related bleeds with short-and longterm mortality after acute coronary syndromes: an analysis from the PLATO trial. EuroIntervention. 2015;11(7):737–745. https://doi.org/10.4244/EIJY14M09_11.; Шахматова О.О., Комаров А.Л., Коробкова В.В., Яровая Е.Б., Андреевская М.В., Шулешова А.Г., Панченко Е.П. Кровотечения из верхних отделов желудочно-кишечного тракта у пациентов со стабильной ишемической болезнью сердца (по результатам проспективного РЕГистра длительной Антитромботической ТерАпии – РЕГАТА). Терапевтический архив. 2020;(9):30–38. https://doi.org/10.26442/00403660.2020.09.000699.; Costa F., van Klaveren D., James S., Heg D., Räber L., Feres F. et al. Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score: a pooled analysis of individual-patient datasets from clinical trials. Lancet. 2017;389(10073):1025–1034. https://doi.org/10.1016/S0140-6736(17)30397-5.; Urban P., Mehran R., Colleran R., Angiolillo D.J., Byrne R.A., Capodanno D. et al. Defining high bleeding risk in patients undergoing percutaneous coronary intervention: a consensus document from the Academic Research Consortium for High Bleeding Risk. Eur Heart J. 2019;40(31):2632–2653. https://doi.org/10.1093/eurheartj/ehz372.; Минушкина Л.О., Эрлих А.Д., Бражник В.А., Затейщиков Д.А. Внешняя валидация шкалы риска кровотечений ОРАКУЛ с помощью базы данных регистра РЕКОРД 3. Кардиология. 2019;(12):5–10. https://doi.org/10.18087/cardio.2019.12.n677.; Cannon C.P., Bhatt D.L., Oldgren J., Lip G.Y.H., Ellis S.G., Kimura T. et al. Dual Antithrombotic Therapy with Dabigatran after PCI in Atrial Fibrillation. N Engl J Med. 2017;377(16):1513–1524. https://doi.org/10.1056/NEJMoa1708454.; Gibson C.M., Mehran R., Bode C., Halperin J., Verheugt F.W., Wildgoose P. et al. Prevention of Bleeding in Patients with Atrial Fibrillation Undergoing PCI. Engl J Med. 2016;375(25):2423–2434. https://doi.org/10.1056/NEJMoa1611594.; Vranckx P., Valgimigli M., Eckardt L., Tijssen J., Lewalter T., Gargiulo G. et al. Edoxaban-based versus vitamin K antagonist-based antithrombotic regimen after successful coronary stenting in patients with atrial fibrillation (ENTRUST-AF PCI): a randomised, open-label, phase 3b trial. Lancet. 2019;394(10206):1335–1343. https://doi.org/10.1016/S0140-6736(19)31872-0.; Lopes R.D., Heizer G., Aronson R., Vora A.N., Massaro T., Mehran R. et al. Antithrombotic Therapy after Acute Coronary Syndrome or PCI in Atrial Fibrillation. N Engl J Med. 2019;380(16):1509–1524. https://doi.org/10.1056/NEJMoa1817083.; Oldgren J., Steg P.G., Hohnloser S.H., Lip G.Y.H., Kimura T., Nordaby M. et al. Dabigatran dual therapy with ticagrelor or clopidogrel after percutaneous coronary intervention in atrial fibrillation patients with or without acute coronary syndrome: a subgroup analysis from the RE-DUAL PCI trial. Eur Heart J. 2019;40(19):1553–1562. https://doi.org/10.1093/eurheartj/ehz059.; Casula M., Fortuni F., Ferlini M., Fabris F., Oltrona Visconti L., Leonardi S. Meta-Analysis Comparing Potent Oral P2Y12 Inhibitors versus Clopidogrel in Patients with Atrial Fibrillation Undergoing Percutaneous Coronary Intervention. Am J Cardiovasc Drugs. 2021;21(2):231–240. https://doi.org/10.1007/s40256-020-00436-8.; Jackson L.R. 2nd, Ju C., Zettler M., Messenger J.C., Cohen D.J., Stone G.W. et al. Outcomes of Patients With Acute Myocardial Infarction Undergoing Percutaneous Coronary Intervention Receiving an Oral Anticoagulant and Dual Antiplatelet Therapy: A Comparison of Clopidogrel Versus Prasugrel From the TRANSLATE-ACS Study. JACC Cardiovasc Interv. 2015;8(14):1880–1889. https://doi.org/10.1016/j.jcin.2015.08.018.; 2021 ESC/EACTS Guidelines for the management of valvular heart disease: Developed by the Task Force for the management of valvular heart disease of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2022;ehac051. https://doi.org/10.1093/eurheartj/ehac051.; Gevaert S.A., Halvorsen S., Sinnaeve P.R., Sambola A., Gulati G., Lancellotti P. et al. Evaluation and management of cancer patients presenting with acute cardiovascular disease: a Consensus Document of the Acute CardioVascular Care (ACVC) association and the ESC council of Cardio-Oncology-Part 1: acute coronary syndromes and acute pericardial diseases. Eur Heart J Acute Cardiovasc Care. 2021;10(8):947–959. https://doi.org/10.1093/ehjacc/zuab056.; Schmucker J., Fach A., Osteresch R., Mata Marin L.A., Retzlaff T., Rühle S. et al. Temporal trends in treatment strategies and clinical outcomes among patients with advanced chronic kidney disease and ST-elevation myocardial infarctions: results from the Bremen STEMI registry. BMC Cardiovasc Disord. 2022;22(1):142. https://doi.org/10.1186/s12872-022-02573-1.; Edfors R., Sahlén A., Szummer K., Renlund H., Evans M., Carrero J.J. et al. Outcomes in patients treated with ticagrelor versus clopidogrel after acute myocardial infarction stratified by renal function. Heart. 2018;104(19):1575–1582. https://doi.org/10.1136/heartjnl-2017-312436.; Roh J.W., Lee S.J., Kim B.K., Hong S.J., Kim H.Y., Ahn C.M. et al. Ticagrelor vs. Clopidogrel in Acute Coronary Syndrome Patients With Chronic Kidney Disease After New-Generation Drug-Eluting Stent Implantation. Front Cardiovasc Med. 2022;8:707722. https://doi.org/10.3389/fcvm.2021.707722.; Park S., Choi Y.J., Kang J.E., Kim M.G., Jung Geum M., Kim S.D. et al. P2Y12 Antiplatelet Choice for Patients with Chronic Kidney Disease and Acute Coronary Syndrome: A Systematic Review and Meta-Analysis. J Pers Med. 2021;11(3):222. https://doi.org/10.3390/jpm11030222.; Goto S., Huang C.H., Park S.J., Emanuelsson H., Kimura T. Ticagrelor vs. clopidogrel in Japanese, Korean and Taiwanese patients with acute coronary syndrome. Circ J. 2015;79(11):2452–2460. https://doi.org/10.1253/circj.CJ-15-0112.; Park D.W., Kwon O., Jang J.S., Yun S.C., Park H., Kang D.Y. et al. TICAKOREA Investigators. Clinically Significant Bleeding With Ticagrelor Versus Clopidogrel in Korean Patients With Acute Coronary Syndromes Intended for Invasive Management: a Randomized Clinical Trial. Circulation. 2019;140(23):1865–1877. https://doi.org/10.1161/CIRCULATIONAHA.119.041766.; Numasawa Y., Sawano M., Fukuoka R., Ejiri K., Kuno T., Shoji S., Kohsaka S. Antithrombotic Strategy for Patients with Acute Coronary Syndrome: A Perspective from East Asia. J Clin Med. 2020;9(6):1963. https://doi.org/10.3390/jcm9061963.; Mirzaev K.B., Rytkin E., Ryzhikova K.A., Grishina E.A., Sozaeva Z.A., Fedorinov D.S. et al. The ABCB1, CYP2C19, CYP3A5 and CYP4F2 genetic polymorphisms and platelet reactivity in the early phases of acute coronary syndromes. Drug Metab Pers Ther. 2018;33(3):109–118. https://doi.org/10.1515/dmpt-2018-0006.; Комаров А.Л., Шахматова О.О., Илющенко Т.А., Донников А.Е., Добровольский А.Б., Панченко Е.П. Оценка риска сердечно-сосудистых осложнений у больных стабильной ИБС, получающих клопидогрел: функция тромбоцитов или генетические исследования? Доктор.Ру. 2012;(6):11–19. Режим доступа: https://www.elibrary.ru/item.asp?id=18302256.; Man M., Farmen M., Dumaual C., Teng C.H., Moser B., Irie S. et al. Genetic variation in metabolizing enzyme and transporter genes: comprehensive assessment in 3 major East Asian subpopulations with comparison to Caucasians and Africans. J Clin Pharmacol. 2010;50(8):929–940. https://doi.org/10.1177/0091270009355161.; Nijjer S.S., Watson G., Athanasiou T., Malik I.S. Safety of clopidogrel being continued until the time of coronary artery bypass grafting in patients with acute coronary syndrome: a meta-analysis of 34 studies. Eur Heart J. 2011;32(23):2970–2988. https://doi.org/10.1093/eurheartj/ehr151.; Montalescot G., Wiviott S.D., Braunwald E., Murphy S.A., Gibson C.M., McCabe C.H., Antman E.M. Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial. Lancet. 2009;373:723–731. https://doi.org/10.1016/S0140-6736(09)60441-4.; Cuisset T., Deharo P., Quilici J., Johnson T.W., Deffarges S., Bassez C. et al. Benefit of switching dual antiplatelet therapy after acute coronary syndrome: the TOPIC (timing of platelet inhibition after acute coronary syndrome) randomized study. Eur Heart J. 2017;38:3070–3078. https://doi.org/10.1093/eurheartj/ehx175.; Kim C.J., Park M.W., Kim M.C., Choo E.H., Hwang B.H., Lee K.Y. et al. Unguided de-escalation from ticagrelor to clopidogrel in stabilised patients with acute myocardial infarction undergoing percutaneous coronary intervention (TALOS-AMI): an investigator-initiated, open-label, multicentre, non-inferiority, randomised trial. Lancet. 2021;398(10308):1305–1316. https://doi.org/10.1016/S0140-6736(21)01445-8.; Sibbing D., Aradi D., Jacobshagen C., Gross L., Trenk D., Geisler T. et al. A randomized trial on platelet function-guided de-escalation of antiplatelet treatment in ACS patients undergoing PCI. Rationale and design of the Testing Responsiveness to Platelet Inhibition on Chronic Antiplatelet Treatment for Acute Coronary Syndromes (TROPICAL-ACS) trial. Thromb Haemost. 2017;117(1):188–195. https://doi.org/10.1160/TH16-07-0557.; Claassens D.M.F., Vos G.J.A., Bergmeijer T.O., Hermanides R.S., van ‘t Hof A.W.J., van der Harst P. et al. A genotypeguided strategy for oral P2Y12 inhibitors in primary PCI. N Engl J Med. 2019;381(17):1621–1631. https://doi.org/10.1056/NEJMoa1907096.; Shehata J., Abdelazeem B., Abbas K., El-Shahat N.A., Baral N., Adhikari G. et al. De-escalation from prasugrel or ticagrelor to clopidogrel in acute coronary syndrome patients undergoing percutaneous coronary intervention: a meta-analysis of randomized clinical trials. J Am Coll Cardiol. 2022;22(3):287–298. https://doi.org/10.1007/s40256-021-00504-7.; Bai N., Ma Y., Niu Y., Zhong P.Y., Shang Y.S., Wang Z.L. Efficacy and safety of de-escalation of antiplatelet therapy after percutaneous coronary intervention in patients with acute coronary syndrome: a meta-analysis of randomized clinical trials. J Cardiovasc Pharmacol. 2022. https://doi.org/10.1097/FJC.0000000000001274.; Shoji S., Kuno T., Fujisaki T., Takagi H., Briasoulis A., Deharo P. et al. De-Escalation of Dual Antiplatelet Therapy in Patients With Acute Coronary Syndromes. J Am Coll Cardiol. 2021;78(8):763–777. https://doi.org/10.1016/j.jacc.2021.06.012.; Mega J.L., Braunwald E., Wiviott S.D., Bassand J.P., Bhatt D.L., Bode C. et al. ATLAS ACS 2–TIMI 51 Investigators. Rivaroxaban in Patients with a Recent Acute Coronary Syndrome. N Engl J Med. 2012;366(1):9–19. https://doi.org/10.1056/NEJMoa1112277.; https://www.aterotromboz.ru/jour/article/view/269

Διαθεσιμότητα: https://www.aterotromboz.ru/jour/article/view/269
https://doi.org/10.21518/2307-1109-2022-12-1-30-45

View record from BASE

6

Academic Journal

Methodology for forecasting assessing the effectiveness of the asymmetric response of the armed forces of Ukraine to threats in the military sphere

Πηγή: Modern Information Technologies in the Sphere of Security and Defence; Том 37, № 1 (2020); 171-178
Современные информационные технологии в сфере безопасности и обороны; Том 37, № 1 (2020); 171-178
Сучасні інформаційні технології у сфері безпеки та оборони; Том 37, № 1 (2020); 171-178

Θεματικοί όροι: military security, threat, asymmetric counteraction, force pressure, military force, effectiveness of counteraction, armed conflict, de-escalation of the threat, воєнна безпека, загроза, асиметрична протидія, силовий тиск, військова сила, ефективність протидії, збройний конфлікт, деескалація загрози, 16. Peace & justice, военная безопасность, угроза, асимметричное противодействие, силовое давление, военная сила, эффективность противодействия, вооруженный конфликт, деэскалация угрозы

Περιγραφή αρχείου: application/pdf

Σύνδεσμος πρόσβασης: http://sit.nuou.org.ua/article/view/198841

View record at OpenAIRE Full Text Finder

7

Academic Journal

Empirical antimicrobial therapy of purulent-septic complications in surgical coloproctology ; Эмпирическая антимикробная терапия гнойно-септических осложнений в хирургической колопроктологии

Συγγραφείς: Yu. M. Stoiko, V. G. Gusarov, A. L. Levchuk, A. V. Maksimenkov, D. A. Kolozyan, Ю. М. Стойко, В. Г. Гусаров, А. Л. Левчук, А. В. Максименков, Д. А. Колозян

Πηγή: Wounds and wound infections. The prof. B.M. Kostyuchenok journal; Том 6, № 2 (2019); 17-23 ; Раны и раневые инфекции. Журнал имени проф. Б.М. Костючёнка; Том 6, № 2 (2019); 17-23 ; 2500-0594 ; 2408-9613

Θεματικοί όροι: деэскалация, purulent-septic complications, antibiotic therapy, protocol, antibiotic consumption, de-escalation, гнойно-септические осложнения, антибиотикотерапия, протокол, потребление антибиотиков

Περιγραφή αρχείου: application/pdf

Relation: https://www.riri.su/jour/article/view/178/176; Хирургические инфекции кожи и мягких тканей : Российские национальные рекомендации / под ред. Б. Р. Гельфанда, В. А. Кубышкина, Р. С. Козлова, Н. Н. Хачатрян. М.: [б. и.], 2015. 109 с.; Абдоминальная хирургическая инфекция : Российские национальные рекомендации / ред. B. C. Савельева, Б. Р. Гельфанда. М.: Боргес, 2011. 98 с.; Программа СКАТ (Стратегия Контроля Антимикробной Терапии) при оказании стационарной медицинской помощи: Российские клинические рекомендации / под ред. С. В. Яковлева, Н. И. Брико, С. В. Сидоренко, Д. Н. Проценко. М.: Изд-во «Перо», 2018. 156 с.; Стратегия и тактика использования антимикробных средств в ЛПУ России: Российские национальные рекомендации / под ред. В. С. Савельева, Б. Р. Гельфанда, С. В. Яковлева. М.:[б. и.], 2012. 94 с.; Гусаров В. Г., Лашенкова Н. Н., Петрова Н. В. и др. Протоколы эмпирической антимикробной терапии как инструмент улучшения качества неотложной медицинской помощи пациентам с инфекцией в многопрофильном хирургическом стационаре // Медицинский алфавит. 2016. Т. 4, № 33. С. 24–28; Гусаров В. Г., Замятин М. Н., Теплых Б. А. и др. Антибиотикорезистентность: пути решения проблемы в многопрофильном стационаре // Вестник Национального медико-хирургического Центра им. Н. И. Пирогова. 2014. Т. 9, № 3. С. 108–112; Zamyatin M., Gusarov V., Petrova N., Lashenkova N., Dementienko M., Shilkin D., Nesterova E. Results of antimicrobial stewardship program implementation in multidisciplinary hospital // ICU Management & Practice. 2018. Vol. 18, № 2. P. 125–127.; Хачатрян Н. Н., Карсотьян Г. С., Исаев А. И., Дибиров Т. М. Послеоперационные инфекционные осложнения: профилактика и лечение в условиях нарастающей резистентности микроорганизмов // Инфекции в хирургии. 2017. Т. 15, № 1. С. 41–49; Tacconelli E., De Angelis G., Cataldo M. A., et al. Does antibiotic exposure increase the risk of methicillinresistant Staphylococcus aureus (MRSA) isolation? A systematic review and meta-analysis // J. Antimicrob. Chemother. 2008. Vol. 61. P. 26–38.; Эпидемиологическое наблюдение за инфекциями, связанными с оказанием медицинской помощи: Федеральные клинические рекомендации / под ред. Б. И. Асланова, Л. П. Зуевой, А. В. Любимова и др. М.: [б. и.], 2014. 60 c.; https://www.riri.su/jour/article/view/178

Διαθεσιμότητα: https://www.riri.su/jour/article/view/178
https://doi.org/10.25199/2408-9613-2019-6-2-17-23

View record from BASE

8

Academic Journal

PRASUGREL FOR THE TREATMENT OF ACUTE CORONARY SYNDROMES AND PERCUTANEOUS CORONARY INTERVENTION: STATUS UPDATE ON THE PROBLEM ; ПРАСУГРЕЛ В ЛЕЧЕНИИ ПАЦИЕНТОВ С ОСТРЫМ КОРОНАРНЫМ СИНДРОМОМ И ЧРЕСКОЖНЫМ КОРОНАРНЫМ ВМЕШАТЕЛЬСТВОМ: СОВРЕМЕННОЕ СОСТОЯНИЕ ПРОБЛЕМЫ

Συγγραφείς: O. O. Shakhmatova, A. L. Komarov, О. О. Шахматова, А. Л. Комаров

Πηγή: Aterotromboz = Atherothrombosis; № 1 (2018); 52-66 ; Атеротромбоз; № 1 (2018); 52-66 ; 2658-5952 ; 2307-1109 ; 10.21518/2307-1109-2018-1

Θεματικοί όροι: деэскалация, thienopyridine, stent thrombosis, acute coronary syndrome, percutaneous coronary intervention, myocardial infarction, bleeding, de-escalation, тиенопиридин, тромбоз стента, острый коронарный синдром, чрескожное коронарное вмешательство, инфаркт миокарда, кровотечения

Περιγραφή αρχείου: application/pdf

Relation: https://www.aterotromboz.ru/jour/article/view/150/193; Farid NA, Kurihara A, Wrighton SA. Metabolism and disposition of the thienopyridine antiplatelet drugs ticlopidine, clopidogrel, and prasugrel in humans. J Clin Pharmacol, 2010, 50: 126–142. doi:10.1177/0091270009343005.; O’Gara PT, Kushner FG, Ascheim DD et al. 2013 ACCF / AHA Guideline for the Management of ST-Elevation Myocardial Infarction. Circulation, 2013, 127: e362-e425.; Ibanez B, James S, Agewall S et al. ESC Scientific Document Group, 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). European Heart Journal, 2018 January 7, 39 (Issue 2): 119–177. https://doi.org/10.1093/eurheartj/ehx393; Amsterdam EA, Wenger NK, Brindis RG et al. 2014 AHA / ACC Guideline for the Management of Patients With Non – ST-Elevation Acute Coronary Syndromes: Executive Summary. Circulation, 2014, 130: 2354–2394.; Roffi M, Patrono C, Collet J-P et al. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). European Heart Journal, 2016 January14, 37 (Issue 3): 267–315. https://doi.org/10.1093/eurheartj/ehv320; Valgimigli M, Bueno H, Byrne RA et al. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS. European Heart Journal, 2017, 0: 1–48. doi:10.1093/eurheartj/ehx419.; Wiviott SD, Braunwald E, McCabe CH et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med, 2007, 357 (20): 2001–2015.; Wilcox R, Iqbal K, Costigan T et al. An analysis of TRITON-TIMI 38, based on the 12 month recommended length of therapy in the European label for prasugrel. Curr Med Res Opin, 2014, 30: 2193–205. doi:10.1185/03007995.2014.944638.; Montalescot G, Bolognese L, Dudek D et al. ACCOAST Investigators. Pretreatment with prasugrel in non-ST-segment elevation acute coronary syndromes. N Engl J Med, 2013, 369: 999–1010. doi:10.1056/NEJMoa1308075.; Antman EM, Wiviott SD, Murphy SA et al. Early and late benefits of Prasugrel in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a TRITON-TIMI 38 (TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet InhibitioN with Prasugrel-Thrombolysis In Myocardial Infarction) analysis. J Am Coll Cardiol, 2008, 51 (21): 2028–2033.; Angiolillo DJ, Rollini F, Storey RF et al. International Expert Consensus on Switching Platelet P2Y12 Receptor – Inhibiting Therapies. Circulation. 2017, 136: 1955–1975. doi:10.1161/CIRCULATIONAHA.117.031 164.; Alexopoulos D, Xanthopoulou I, Deftereos S et al. In-hospital switching of oral P2Y12 inhibitor treatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention: prevalence, predictors and short-term outcome. Am Heart J, 2014, 167: 68–76.e2. doi:10.1016/j.ahj.2013.10.010.; Clemmensen P, Grieco N, Ince H et al. MULTIPRAC study investigators. MULTInational non-interventional study of patients with ST-segment elevation myocardial infarction treated with PRimary Angioplasty and Concomitant use of upstream antiplatelet therapy with prasugrel or clopidogrel: the European MULTIPRAC Registry. Eur Heart J Acute Cardiovasc Care, 2015, 4: 220–229. doi:10.1177/2048872614547449.; Bagai A, Peterson ED, Honeycutt E et al. In-hospital switching between adenosine diphosphate receptor inhibitors in patients with acute myocardial infarction treated with percutaneous coronary intervention: insights into contemporary practice from the TRANSLATEACS study. Eur Heart J Acute Cardiovasc Care, 2015, 4: 499–508. doi:10.1177/2048872614564082.; Schiele F, Puymirat E, Bonello L et al. Switching between thienopyridines in patients with acute myocardial infarction and quality of care. Open Heart, 2016, 3: e000384. doi:10.1136/openhrt-2015–000384.; De Luca L, Leonardi S, Cavallini C et al. EYESHOT Investigators. Contemporary antithrombotic strategies in patients with acute coronary syndrome admitted to cardiac care units in Italy: the EYESHOT study. Eur Heart J Acute Cardiovasc Care, 2015, 4: 441–452. doi:10.1177/2048872614560505.; Bagai A, Wang Y, Wang TY et al. In-hospital switching between clopidogrel and prasugrel among patients with acute myocardial infarction treated with percutaneous coronary intervention: insights into contemporary practice from the National Cardiovascular Data Registry. Circ Cardiovasc Interv, 2014, 7: 585–593. doi:10.1161/CIRCINTERVENTIONS.114.001555.; Zettler ME, Peterson ED, McCoy LA et al. TRANSLATEACS Investigators. Switching of adenosine diphosphate receptor inhibitor after hospital discharge among myocardial infarction patients: insights from the Treatment with Adenosine Diphosphate Receptor Inhibitors: Longitudinal Assessment of Treatment Patterns and Events after Acute Coronary Syndrome (TRANSLATE-ACS) observational study. Am Heart J, 2017, 183: 62–68. doi:10.1016/j.ahj.2016.10.006.; De Luca L, D’Ascenzo F, Musumeci G et al. Incidence and outcome of switching of oral platelet P2Y12 receptor inhibitors in patients with acute coronary syndromes undergoing percutaneous coronary intervention: the SCOPE registry. EuroIntervention, 2017, 13: 459–466. doi:10.4244/EIJD-17–00092.; Cuisset T, Deharo P, Quilici J et al. Benefit of switching dual antiplatelet therapy after acute coronary syndrome: the TOPIC (Timing of Platelet Inhibition After Acute Coronary Syndrome) randomized study. Eur Heart J, 2017 Nov 1, 38 (41): 3070–3078. doi:10.1093/eurheartj/ehx175.; Sibbing D, Aradi D, Jacobshagen C et al. Guided deescalation of antiplatelet treatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention (TROPICAL-ACS): a randomised, open-label, multicentre trial. Lancet, 2017, 390: 1747– 1757. doi:10.1016/S0140–6736(17)32155–4.; Motovska Z, Hlinomaz O, Miklik R et al. Prasugrel versus Ticagrelor in Patients with Acute Myocardial Infarction Treated with Primary Percutaneous Coronary Intervention. Multicenter Randomized PRAGUE-18 Study. Circulation, 2016 Nov 22, 134 (21): 1603–1612.; Motovska Z, Hlinomaz O, Kala P et al. 1-Year Outcomes of Patients Undergoing Primary Angioplasty for Myocardial Infarction Treated With Prasugrel Versus Ticagrelor. J Am Coll Cardiol, 2018 Jan 30, 71 (4): 371–381. doi:10.1016/j.jacc.2017.11.008.; Bundhun PK, Shi J-X, Huang F. Head to head comparison of Prasugrel versus Ticagrelor in patients with acute coronary syndrome: a systematic review and meta-analysis of randomized trials. BMC Pharmacology and Toxicology, 2017, 18: 80. doi:10.1186/s40360-017-0189–7.; Sakurai R, Burazor I, Bonneau HN, Kaneda H. Headtohead comparison of prasugrel versus ticagrelor in patients undergoing percutaneous coronary intervention: A meta-analysis of randomized controlled trials. J Interv Cardiol, 2017 Oct, 30 (5): 457–464. doi:10.1111/joic.12416.; Larmore C, Effron MB, Molife C et al. «Real-world» comparison of prasugrel with ticagrelor in patients with acute coronary syndrome treated with percutaneous coronary intervention in the United States, Catheter. Cardiovasc. Interv., 2016, 88 (4): 535–544.; Danchin N, Lettino M, Zeymer U et al. Use, patient selection and outcomes of P2Y12 receptor inhibitor treatment in patients with STEMI based on contemporary European registries. Eur Heart J Cardiovasc Pharmacother, 2016, 2: 152–167. doi:10.1093/ehjcvp/pvw003.; Rezaei SS, Geroldinger A, Heinze G et al. Clopidogrel, prasugrel, or ticagrelor use and clinical outcome in patients with acute coronary syndrome: A nationwide long-termregistry analysis from 2009 to 2014. International Journal of Cardiology, 2017, 235: 61–66.; Alexopoulos D, Xanthopoulou I, Deftereos S et al. Contemporary antiplatelet treatment in acute coronary syndrome patients undergoing percutaneous coronary intervention: one-year outcomes from the Greek AntiPlatelet Registry (GRAPE). J Thromb Haemost, 2016 Jun, 14 (6): 1146–54. doi:10.1111/jth.13316.; https://www.aterotromboz.ru/jour/article/view/150

Διαθεσιμότητα: https://www.aterotromboz.ru/jour/article/view/150
https://doi.org/10.21518/2307-1109-2018-1-52-66

View record from BASE

9

Academic Journal

РОЛЬ МЕЖДУНАРОДНОГО СОТРУДНИЧЕСТВА В УРЕГУЛИРОВАНИИ ВООРУЖЕННОГО КОНФЛИКТА НА УКРАИНЕ (2014-2015)

Συγγραφείς: ШУМИЛОВ МИХАИЛ МИХАЙЛОВИЧ

Θεματικοί όροι: ДЕЭСКАЛАЦИЯ,"НОРМАНДСКАЯ ЧЕТВЕРКА","НОРМАНДСКИЙ ФОРМАТ",ОРГАНИЗАЦИЯ ПО БЕЗОПАСНОСТИ И СОТРУДНИЧЕСТВУ В ЕВРОПЕ (ОБСЕ),СОВЕТ БЕЗОПАСНОСТИ ООН,СПЕЦИАЛЬНАЯ МОНИТОРИНГОВАЯ МИССИЯ МЕЖДУНАРОДНЫХ НАБЛЮДАТЕЛЕЙ ОБСЕ НА УКРАИНЕ (СММ),ПОСТОЯННЫЙ СОВЕТ ОБСЕ,ПАРЛАМЕНТСКАЯ АССАМБЛЕЯ ОБСЕ,ТРОЙКА ОБСЕ,ТРЕХСТОРОННЯЯ КОНТАКТНАЯ ГРУППА ПО УКРАИНЕ,DE-ESCALATION,"NORMAN QUARTET","NORMAN FORMAT",ORGANIZATION FOR SECURITY AND CO-OPERATION IN EUROPE (OSCE),UNITED NATIONS SECURITY COUNCIL,OSCE SPECIAL MONITORING MISSION TO UKRAINE (SMM),THE OSCE PERMANENT COUNCIL,OSCE PARLIAMENTARY ASSEMBLY,OSCE TROIKA,THE TRILATERAL CONTACT GROUP ON UKRAINE

Περιγραφή αρχείου: text/html

Διαθεσιμότητα: http://cyberleninka.ru/article/n/rol-mezhdunarodnogo-sotrudnichestva-v-uregulirovanii-vooruzhennogo-konflikta-na-ukraine-2014-2015
http://cyberleninka.ru/article_covers/16380956.png

View record from BASE

10

Academic Journal